Market cap
$2,213 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
65
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 512.28 | 83.77 | 66.38 |
| EBIT | -- | -- | 80.13 | 19.43 | 10.26 |
| Net Profit | -- | -- | 64.83 | 16.47 | 5.17 |
| EPS | -- | -- | 65.34 | 19.20 | 8.25 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-25 | Dec-24 | Dec-23 |
| EBIT-Margin
| 278.88 | -380.48 | -45.75 | 949.35 | -66.94 |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| 169.50 | 9,029.97 | 31.91 | 201.73 | 274.85 |
| Return on Capital
| 233.61 | 107.32 | 1,208.63 | -401.72 | -106.09 |
| Return on Assets
| -57.20 | -56.42 | -35.45 | -84.47 | -51.67 |
| Debt to Equity (x)
| -- | -- | -1.13 | -0.77 | -27.42 |
Profitability
ROCE
1,208.63
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
1,208.63
|
-401.72
|
-106.09
|
-115.31
|
-48.90
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
31.91
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
31.91
|
201.73
|
274.85
|
44,738.04
|
-96.66
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-35.45
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
-35.45
|
-84.47
|
-51.67
|
-70.62
|
-39.87
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-45.75
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
-45.75
|
949.35
|
-66.94
|
-957.22
|
-1,781.83
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-80.83
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
-80.83
|
947.59
|
-109.64
|
-1,194.33
|
-1,775.71
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
5.12
--
Year on year growth in net sales
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
5.12
|
-1.20
|
6.58
|
0.80
|
0.14
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
80.13
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
80.13
|
-181.63
|
46.98
|
3.07
|
-28.81
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
64.83
--
Year on year growth in profit after tax
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
64.83
|
-71.62
|
30.40
|
-21.36
|
-39.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
0.65
--
Year on year growth in earnings per share
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
0.65
|
-0.41
|
0.38
|
-0.21
|
-0.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-1.13
--
Total debt / Net worth
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
-1.13
|
-0.77
|
-27.42
|
-1.97
|
1.72
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-0.05
--
(Short term borrowings / Net worth)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
-0.05
|
-0.07
|
-2.72
|
-0.17
|
0.31
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.09
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
1.09
|
1.04
|
1.75
|
1.38
|
2.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
--
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
--
|
--
|
1.75
|
1.30
|
2.61
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
-1.30
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
-1.30
|
-8.44
|
-3.04
|
-7.83
|
-67.43
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
25.91
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
25.91
|
-118.71
|
8.19
|
59.51
|
147.13
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.44
--
Sales / Average Total Assets
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
0.44
|
-0.09
|
0.47
|
0.06
|
0.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
99.90
--
Average Debtors / Sales * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
99.90
|
-292.15
|
29.30
|
257.59
|
536.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
--
|
--
|
--
|
-11.50
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
--
|
--
|
--
|
1,667.73
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
--
|
--
|
--
|
-1,421.63
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|